UNSPSC 51202409: Infliximab

This classification denotes a monoclonal antibody with the molecular formula C6428H9912N1694O1987S46, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) B72HH48FLU, more generally known as infliximab. European Medicines Agency schedules infliximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02681MIG. The term INFLIXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 1 1998, list 39.

Most nations, for tariff and trade purposes, schedule infliximab under HS 30021091 and SITC 54163. As of Q4 2014, INFLIXIMAB remains US FDA's Preferred Term for this commodity. Infliximab bears US NLM identifiers UMLS ID C0666743 and NCI Concept Code C1789. SMILES: none.

UNSPSC 51202409 Infliximab is a Commodity code that state and local governments use to tag pharmaceutical procurement, though recent solicitation activity under this code shows a mismatch between the code's nominal scope—a specific immunosuppressant biologic—and the actual work being bought. The recent opportunities posted against this code span emergency medical supplies (naloxone and drug deactivation systems), generic pharmaceutical and OTC products distributed through wholesalers, direct-to-manufacturer prescription fulfillment programs, and first-aid supplies for fire departments. Issuing bodies include state health and human services departments, multistate cooperative purchasing alliances, counties, and cities. The code appears to function as a catch-all pharmaceutical purchasing classification within some jurisdictions' tagging systems, despite infliximab's narrow clinical indication and high cost relative to the volume-based, consumable-supply focus of recent solicitations.

Activity is scattered geographically, with recent opportunities from Florida (Seminole County, IFB 60459723LAS for naloxone and drug deactivation systems, due July 26, 2023), Texas (HHS RFI HHS0017013 for direct-to-manufacturer prescription programs, due April 3, 2026), Florida (City of Tampa IFB 26P00145 for medical and first aid supplies for the fire department, due March 13, 2026; estimated contract value $700,000), and Minnesota (MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products spanning Minnesota and Oregon, proposals due March 26, 2026). The Tampa and MMCAP opportunities indicate active state and local spending on pharmaceutical distribution infrastructure and emergency medical consumables, but the code's nominal scope—infliximab specifically—does not appear to align with what these jurisdictions are actually procuring. Firms evaluating this code should confirm the specific products and therapeutic categories their target customers classify under 51202409 before building pursuit strategy, as tagging inconsistency limits visibility into true demand for any single product line.